PMID- 34529134
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20220301
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Print)
IS  - 0721-832X (Linking)
VI  - 260
IP  - 3
DP  - 2022 Mar
TI  - Non-immediate drug hypersensitivity reactions secondary to intravitreal 
      anti-vascular endothelial growth factors.
PG  - 1005-1014
LID - 10.1007/s00417-021-05353-3 [doi]
AB  - PURPOSE: To describe a series of non-immediate drug hypersensitivity reactions 
      after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). 
      PATIENTS AND METHODS: Retrospective report of 6 patients with cutaneous 
      non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF 
      injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept. 
      RESULTS: Clinical manifestations ranged from mild maculopapular rash, purpura to 
      severe generalized erythroderma, with or without systemic involvement such as 
      microscopic hematuria and proteinuria or fever. In two out of the six patients, 
      reintroduction of either the same or an alternative anti-VEGF drug did induce a 
      recurrence of the drug hypersensitivity reaction, while 4 patients showed no 
      recurrence. CONCLUSION: Cutaneous non-immediate drug hypersensitivity reactions 
      secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or 
      switch to another anti-VEGF may either induce recurrence or be well supported by 
      the patient. The decision of drug discontinuation should be guided by the 
      severity of the disease.
CI  - (c) 2021. The Author(s).
FAU - Moret, E
AU  - Moret E
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland.
FAU - Ambresin, A
AU  - Ambresin A
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland.
FAU - Gianniou, C
AU  - Gianniou C
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland.
FAU - Bijon, J
AU  - Bijon J
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland.
FAU - Besse-Hayat, C
AU  - Besse-Hayat C
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland.
FAU - Bogiatzi, S
AU  - Bogiatzi S
AD  - Department of Medicine, Division of Dermatology and Venereology, Lausanne 
      University Hospital CHUV, Lausanne, Switzerland.
FAU - Hohl, D
AU  - Hohl D
AD  - Department of Medicine, Division of Dermatology and Venereology, Lausanne 
      University Hospital CHUV, Lausanne, Switzerland.
FAU - Spertini, F
AU  - Spertini F
AD  - Department of Medicine, Division of Immunology and Allergy, Lausanne University 
      Hospital CHUV, Lausanne, Switzerland.
FAU - Mantel, I
AU  - Mantel I
AD  - Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, 
      Foundation Asile des Aveugles, Lausanne, Switzerland. irmela.mantel@fa2.ch.
LA  - eng
PT  - Journal Article
DEP - 20210916
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects
MH  - Bevacizumab/adverse effects
MH  - *Drug Hypersensitivity/diagnosis/drug therapy/etiology
MH  - Humans
MH  - Intravitreal Injections
MH  - Ranibizumab/adverse effects
MH  - Receptors, Vascular Endothelial Growth Factor
MH  - Recombinant Fusion Proteins
MH  - Retrospective Studies
MH  - *Vascular Endothelial Growth Factor A
PMC - PMC8850288
OTO - NOTNLM
OT  - Aflibercept
OT  - Bevacizumab
OT  - Cutaneous adverse events
OT  - Drug hypersensitivity reaction
OT  - Intravitreal anti-VEGF
OT  - Ranibizumab
COIS- The authors have no conflicts of interest to declare that are relevant to the 
      content of this article. Irmela Mantel is an occasional consultant to Novartis, 
      Bayer, and Roche.
EDAT- 2021/09/17 06:00
MHDA- 2022/02/19 06:00
PMCR- 2021/09/16
CRDT- 2021/09/16 12:27
PHST- 2021/03/16 00:00 [received]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/07/21 00:00 [revised]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/09/16 12:27 [entrez]
PHST- 2021/09/16 00:00 [pmc-release]
AID - 10.1007/s00417-021-05353-3 [pii]
AID - 5353 [pii]
AID - 10.1007/s00417-021-05353-3 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2022 Mar;260(3):1005-1014. doi: 
      10.1007/s00417-021-05353-3. Epub 2021 Sep 16.